News
AGROGENERATION : First Half 2021 Results
- Commodity price increases led to significant improvement in EBITDA
- Further reductions in administrative and financial costs contributed to a positive net result
- Good visibility on 2021 crop
GROUPE LDLC : CONTINUED GROWTH IN FIRST HALF 2021/2022
- CONSOLIDATED REVENUES UP 6.1% AT €333.5M (UP 5.3% AT CONSTANT CONSOLIDATION SCOPE)
- BTOB BUSINESS UP 20.5% AT €91.6M
- STRONG RESILIENCE OF BTOC BUSINESS AT €236.1M (VS €232.9M IN FIRST HALF
Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
Median Technologies Reports on Its 2021 Half-Year Results and Its Q3 2021 Business Activity Indicators
Regulatory News:
Median Technologies (Euronext Growth - ALMDT) (Paris:ALMDT) whose Board of Directors met on October 21st, 2021 to approve the consolidated financial statements for the first half
STREAMWIDE selected for phase 3 in the european Broadway project within the consortium led by Airbus
_ Paris, October 20, 2021 – Airbus DS SLC-led consortium that includes
NETGEM : Third quarter 2021 activity: Continued growth in Gross Profit Reinforced outlook with the signing of the TalkTalk contract
Paris, October 20, 2021,
NETGEM's activity in the third quarter of 2021 was marked by the good deployment momentum of the NetgemTV platform in B2B (2C) “Content as a service” mode:
- The signing of
THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2021 AND PRESENTS ITS PROGRESS REPORT
Lyon, 19 October 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Median Technologies to Host a Live Webcast and Provide a Company Update on October 25th, 2021
Regulatory News:
Median Technologies (ALMDT:PA) announced today that Fredrik Brag, CEO and founder of Median Technologies, will provide a company update on October 25th, 2021 at 6:00 pm CEST
GenSight Biologics Announces FDA Grant of Fast Track Designation for Optogenetic Therapy GS030 as Treatment for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Netgem announces a new contract with leading British operator TalkTalk Group to supply its NetgemTV platform for the launch of TalkTalk TV 4K
Paris, October 12, 2021,
Netgem (Euronext Growth ALNTG) announces a new contract with leading UK operator TalkTalk Group to supply NetgemTV, its comprehensive multi-screen operated entertainment
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
Regulatory News:
ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies
Sensorion Hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021
Regulatory News:
Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within
GenSight Biologics Announces the Publication of a Review of Gene Therapy Trials for LHON in International Ophthalmology Clinics
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Mauna Kea Technologies Announces 5 Communications Highlighting the Clinical Value of Cellvizio® in Interventional Pulmonology Presented During the European Respiratory Society (ERS) International Congress 2021
Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE)
Valbiotis bietet Überblick über seine Aktivitäten und veröffentlicht Ergebnisse für das erste Halbjahr 2021
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert) (Paris:ALVAL), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und
THERANEXUS ANNOUNCES ITS FIRST HALF 2021 RESULTS
Lyon, 30 September 2021 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
Valbiotis Reviews Its Activities and Publishes Its Financial Report for the First Half of 2021
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible) (Paris:ALVAL), a French research and development company committed to scientific innovation for preventing and combating
Sensorion to Attend Three Conferences in October 2021, Including the Cell & Gene Meeting on the Mesa
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and
TRANSITION EVERGREEN : Half-year results as of 30 June 2021
- H1 2021 net income: €23.0m
- Restated NAV[1] of €78.9m as of 30 June 2021, up 135% during the first half
- Strengthened financing structure after closing through a private placement totalling
BIOCORP und NOVO NORDISK schließen weltweite Partnerschaft im Bereich Diabetes und digitale Gesundheit
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / PEA/KMU-qualifiziert), ein französisches Unternehmen mit Spezialisierung auf die Gestaltung, Entwicklung und Herstellung von innovativen
Sensorion Reports 2021 First Half Results
Regulatory News:
Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN), a pioneering clinical-stage and gene therapy biotech company specializing in the development of novel therapies to restore, treat
BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, today
Valbiotis: Exklusivvereinbarung mit ADECAL Technopole und IFREMER stärkt Entwicklung innovativer natürlicher Gesundheitslösungen durch die Integration der Erforschung von Mikroalgen aus Neukaledonien
Pflichtmitteilung:
Valbiotis (FR0013254851 – ALVAL, PEA/KMU-qualifiziert), ein französisches Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur
AgroGeneration and the European High Growth Opportunities Securitization Fund announce the conclusion of a settlement agreement
Paris, on 24 September 2021
Today, AgroGeneration and the European High Growth Opportunities Securitization Fund announce that they have come to a settlement regarding the ORNANE issuance